Following is a complete list of oncology studies currently enrolling patients. Click on a link to learn more about it.

Brain Cancer Studies

• Phase I/II Trial of Imatinib Mesylate in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma (NCCTG N0272)

Breast Cancer Studies

• Hormone Therapy with or without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer : The TAILORx Trial (ECOG PACCT-1)
• Radiation Therapy in Treating Women Who Have Undergone Surgery for Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer (NSABP B-39/RTOG 0413)
• Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in situ Ressected by Lumpectomy
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (NSABP B-43)
• A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP B-46-I/USOR 07132)
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG E5103)
• A Randomized, Multi-Center, Open-Label, Phase II Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2-Positive Primary Breast Cancer (ALTTO N063D/BIG 2-06)
• Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer (CALGB 40503)

Colon Cancer Studies

• Randomized, Phase III Study Comparing 5-FU, Leucovorin & Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin & Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (ECOG E5202)
• Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuxmimab with or without Bevacizumab as 2nd-Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX (CTSU S0600)

Gynecologic Cancer Studies

• Collecting Tumor Samples from Patients with Gynecological Tumors (GOG 0136)
• Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer (GOG 0212)
• Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (GOG 0213)
• Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries (GOG 0215)
• Phase III Randomized Study of Bevacizumab in Combination with Intravenous Versus Intraperitoneal Chemotherapy in Patients with Stage II or III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma (GOG 0252)
• Phase II Randomized Study of Paclitaxel, Carboplatin, and Bevacizumab Versus Paclitaxel, Carboplatin, and Temsirolimus Versus Ixabepilone, Carboplatin, and Bevacizumab in Patients With Stage III-IV or Recurrent Endometrial Cancer (GOG 0086P)
• A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix (GOG 0240)
• Molecular Staging of Endometrial Cancer (GOG 0210)
• A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Carcinoma (GOG 0249)
• A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked (GOG 0258)

Head & Neck Cancer Studies

• Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)

Leukemia Studies

• Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias
• Predictors of Adult Leukemia in Minnesota (PALM) Study
• Phase II Study of Combination Chemotherapy in Adolescents and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ECOG C10403)
• Phase III Randomized, Double-blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) (CTSU C10603)
• Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy with or without Gemtuzumab Ozogamicin Followed by Maintenance Therapy Comprising Tretinoin, Mercaptopurine and Methotrexate versus Observation in Patients with Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia (CTSU S0521)
• Collecting Tissue Samples from Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial (ECOG E3903)

Lung Cancer Studies

• Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy
• Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery (ECOG E1505)

Lymphoma Studies

• A Two-Arm, Non-Randomized, Multi-Center, Phase II Study of VELCADE® (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Subjects with Relapsed Follicular Lymphoma

Melanoma Studies

• Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients With Stage II or III Melanoma (ECOG E1697)

Multiple Myeloma Studies

• Randomized Phase IIIb Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan and Prednisone (VMP)
• Bone Marker Directed Dosing of ZOMETA® (zoledronic acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma

Myelodysplastic Syndrome Studies

• A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Neuroendocrine Cancer Studies

• Octreotide and Interferon alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (CTSU S0518)

Prostate Cancer Studies

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases (CTSU C90202)
• Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy (CTSU S0421)
• Phase III Randomized Study of Chemohormonal Therapy versus Androgen Ablation Therapy in Patients with Extensive Metastatic Prostate Cancer (ECOG E3805)

Rectal Cancer Studies

• Clinical Trial Comparing Pre-Op Radiation Therapy and Capecitabine with Pre-Op Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-FU in the Treatment of Patients with Operable Carcinoma of the Rectum (NSABP R-04)

Renal Cancer Studies

• Randomized Phase II Study to Determine the Effect of Two Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma (ECOG E4805)
• Randomized, Double-blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG E2805)
• A Randomized Phase II Study of VEGF, RAF Kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma; The BeST Trial (ECOG E2804)

Bone Marrow Transplant Studies

• Fludarabine Based Conditioning for Allogeneic Marrow Transplantation for HLA-Compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN 0301)
• Phase II Trial of Non-Myeloablative, Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN 0701)
• A Mulit-Center, Randomized, Double-Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofeti Versus Corticosteroids with Placebo as Initial Systemic Treatment of Acute GvHD (BMT CTN 0802)
• RDSafe: A Multi-Center Study of Hematopoietic Stem Cell Donor Safety and Quality of Life (CIBMTR 06 DON)

Cancer Control Studies

• Palitaxel-Associated Acute Pain Syndrome Natural History Study (NCCTG N08C1)
• American Ginseng in Treating Patients with Fatigue Caused by Cancer (NCCTG N07C2)